Posted on: January 26, 2022
These BCCDC guidance documents focus on the safety of COVID-19 Vaccines for people with Significant Neuromuscular Conditions Who Require Respiratory Support and Autoimmune Neuromuscular Disorders Receiving Immunosuppressive/ Immunomodulating Therapy. Updates include Moderna will be approved shortly for children aged 6-11, information around 3rd vaccine doses and booster doses.